ImmusanT Secures $20,000,000 Series A Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=125496fc-974b-40d2-ad62-39328ba3a460&Preview=1 -
Date
12/13/2011 -
Company Name
ImmusanT -
Mailing Address
One Broadway 14th Floor Cambridge, MA 02142 -
Company Description
ImmusanT is an early stage biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with celiac disease. -
Website
http://www.immusant.com -
Transaction Type
Venture Equity -
Transaction Amount
$20,000,000 -
Transaction Round
Series A -
Proceeds Purposes
The proceeds will fund the Nexvax2 therapeutic and diagnostic development plan to the point of demonstrating proof-of-concept. ImmusanT expects to initiate the next clinical trial in early 2012. -
M&A Terms
-
Venture Investor
Vatera Healthcare Partners
